Soteria Biotherapeutics
San Francisco
About Soteria Biotherapeutics
Soteria is developing a next generation of conditionally active bispecific t-cell engaging antibodies to treat cancer patients with solid tumors. Soteria’s highly innovative T-LITE™ platform provides small molecule-dependent activation of bispecific antibody therapies, enabling safer and more efficacious treatments through pulsatile activity, reduced side effects and higher dosing.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $100K – $500K
- Total funding: $42.0M
- Funding stage: Early Stage Venture
- Last round: Series A (May 2021)
- Website: soteriabiotherapeutics.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/soteria-biotherapeutics-127888 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.